New Hepatitis C Treatment Option Available for Patients Who Failed DAA Therapy

In a new study published in the New England Journal of Medicine, lead investigator Marc Bourliere, MD, from the Hospital Saint Joseph in Marseilles, and his colleagues conducted 2 phase 3 clinical trials to explore treatment options for those chronically infected with hepatitis C (HCV) who have had no success with DAA therapy. Dr. Bourliere et al’s first trial, POLARIS-1, involved 300 patients with HCV genotype 1 who had previously received a drug combi

Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges?

Within the next few years, several pipeline hepatitis C (HCV) drugs are expected to be approved in the United States, ensuring that even the most difficult-to-treat patients will soon be able to be cured, according to experts interviewed at The Liver Meeting in Boston. "Very few patients are being warehoused because there are only a few very niche special populations left," noted Robert Brown, M.D., M.P.H., Gladys and Roland Harriman Professor of Medicine